Nature of Disclosure: Regulatory filing pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the outcome of a board meeting and completion of a warrant conversion.

Key Event: The Board of Directors of Shelter Pharma Limited, at its meeting held on October 16, 2026, approved the conversion of 465,000 convertible equity warrants into an equivalent number of equity shares. This conversion was exercised by the warrant holder, Mr. Mustaqim Nisarahmed Sabugar (a promoter), pursuant to the terms of a preferential allotment.

Background and Previous Disclosures: This is a continuation of a previous disclosure dated August 6, 2025. The initial preferential allotment of 880,800 warrants was approved by shareholders at an Extraordinary General Meeting on July 23, 2025, and received in-principle approval from BSE Limited (Ref: LOD/PREF/AM/FIP/572/2025-26) on July 22, 2025. The warrants were allotted at an issue price of ₹42.25 each, with 25% of the amount paid upfront at the time of allotment.

Details of Current Conversion:

  • Number of Warrants Converted: 465,000
  • Number of Equity Shares Allotted: 465,000
  • Face Value per Share: ₹10
  • Remaining Exercise Price Paid: ₹31.6875 per warrant (75% of the ₹42.25 issue price)
  • Total Funds Received: ₹1,47,34,687.50 (Fourteen Million Seven Hundred Thirty-Four Thousand Six Hundred Eighty-Seven Rupees and Fifty Paise)
  • Warrant Holder: Mustaqim Nisarahmed Sabugar (Promoter)
  • Resulting Shareholding Change: The promoter's entire allotment of 750,000 warrants is now fully converted, with 285,000 shares allotted previously and 465,000 shares allotted in this tranche.

Capital Structure Impact:

  • Pre-Conversion Paid-Up Capital: ₹16,83,67,920 (consisting of 16,836,792 equity shares of ₹10 each)
  • Post-Conversion Paid-Up Capital: ₹17,30,17,920 (consisting of 17,301,792 equity shares of ₹10 each)
  • Increase in Capital: ₹46,50,000

The newly allotted equity shares will rank pari-passu with the existing equity shares of the company. An application for listing and trading approval for these new shares will be made to the stock exchange in due course.

Meeting Details: The board meeting commenced at 2:30 PM and concluded at 3:00 PM on October 16, 2026.

Annexures:

  • Annexure I provides a detailed breakdown of the conversion, confirming one investor (a promoter) converted 465,000 warrants, paying ₹1,47,34,687.50, resulting in zero outstanding warrants.
  • Annexure II contains the standard disclosures required under SEBI Regulation 30, confirming the issuance type was a preferential allotment on conversion of warrants, involving one investor.